ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultNabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSmith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774 · cited 1×
“A number of studies have demonstrated significant activity of endocrine therapy, particularly in luminal A-like disease [37–40].”
BackgroundMouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746 · cited 1×
“500 mg, every 4 weeks) [77–88].”
INTERNATIONALCOLLABORATIVEHYPERT, VERNON, C., HAND, J., FIELD, S., MACHIN, D., WHALEY, J., ZEE, J., VANPUTTEN, W., VANRHOON, G., & VANDIJK, J. (1996) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/0360-3016(96)00154-x · Cited by 725 · cited 1×
“complete response: 24%–31% in the no-hyperthermia arm versus 57%–68% in the hyperthermia arm) [72, 73].”
BackgroundKrop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724 · cited 1×
“treatment of physician's choice, in the TH3RESA trial) [101].”
BackgroundSelf-citationBachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703 · cited 1×
“Overall survival prolongation was also observed, in an exploratory analysis of the randomized phase II TAMRAD study comparing combination of tamoxifen and everolimus to tamoxifen alone in AIresistant patients [92].”
MethodThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646 · cited 1×
“However, there is an accumulating body of evidence suggesting that the frequency and severity of many symptoms that impact upon an individual patient's quality of life go under-reported, under-recognised and consequently under-treated [21].”
BackgroundDi Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636 · cited 1×
“1-month difference in median OS compared with fulvestrant 250 mg [80].”
BackgroundPiccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Self-citationBiganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Reed, M., Ciatto, S., Voogd, A. C., Brain, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70383-7 · Cited by 567
Self-citationRandomized Trial of Hyperthermia and Radiation for Superficial Tumors
Jones, E. L., Oleson, J. R., Prosnitz, L. R., Samulski, T. V., Vujaskovic, Z., Yu, D., Sanders, L. L., & Dewhirst, M. W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.520 · Cited by 560 · cited 1×
“complete response: 24%–31% in the no-hyperthermia arm versus 57%–68% in the hyperthermia arm) [72, 73].”
BackgroundEllis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551 · cited 1×
“A number of studies have demonstrated significant activity of endocrine therapy, particularly in luminal A-like disease [37–40].”
BackgroundYardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Self-citationByrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516 · cited 1×
“However, available data suggest their promising activity mostly in the neoadjuvant setting [46,47], and to a lesser degree in advanced disease [48].”
BackgroundChia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Self-citationDawood, S., Merajver, S. D., Viens, P., Vermeulen, P. B., Swain, S. M., Buchholz, T. A., Dirix, L. Y., Levine, P. H., Lucci, A., Krishnamurthy, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq345 · Cited by 488 · cited 3×
“A more homogenous form of LABC is inflammatory breast cancer (IBC), a distinct clinic-pathologic entity.”
BackgroundKaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., & Cortes, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4892 · Cited by 463
HEMSELL, D. L., GRODIN, J. M., BRENNER, P. F., SIITERI, P. K., & MACDONALD, P. C. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-38-3-476 · Cited by 444
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., Costa, A., Winer, E. P., Cardoso, F., & on behalf of the ESO-MBC Task Force (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq029 · Cited by 422
Self-citationBrufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationBlum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · Cited by 398
Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., Kabbaj, O., Spano, J. P., Marsiglia, H., Rouzier, R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.095 · Cited by 394 · cited 1×
“Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6].”
BackgroundSelf-citationPrognostic factors in 1038 women with metastatic breast cancer
Largillier, R., Ferrero, J.-M., Doyen, J., Barriere, J., Namer, M., Mari, V., Courdi, A., Hannoun-Levi, J. M., Ettore, F., Birtwisle-Peyrottes, I., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn424 · Cited by 373
Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y., Petrakova, K., Dube, P., & Tosello de Oliveira, C. (2006) · Cancer · doi:10.1002/cncr.21872 · Cited by 352 · cited 1×
“A number of studies have demonstrated significant activity of endocrine therapy, particularly in luminal A-like disease [37–40].”
BackgroundNational Cancer Institute Patient Navigation Research Program: Methods, protocol, and measures
Freund, K. M., Battaglia, T. A., Calhoun, E., Dudley, D. J., Fiscella, K., Paskett, E., Raich, P. C., Roetzheim, R. G., & The Patient Navigation Research Program Group (2008) · Cancer · doi:10.1002/cncr.23960 · Cited by 340
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340 · cited 1×
“However, available data suggest their promising activity mostly in the neoadjuvant setting [46,47], and to a lesser degree in advanced disease [48].”
BackgroundParidaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Self-citationSawada, N., Ishikawa, T., Sekiguchi, F., Tanaka, Y., & Ishitsuka, H. (1999) · PubMed · Cited by 319
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Self-citationO’Shaughnessy, J. A., Blum, J., Moiseyenko, V., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 304 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Result1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.03.003 · Cited by 303
Self-citationAndersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294 · cited 1×
“Vinorelbine yielded equal or superior results to both paclitaxel and docetaxel, when combined with trastuzumab in the HER-2-positive ABC in the HERNATA [113] and TRAVIOTA trials [114].”
ResultSelf-citationJohnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70322-x · Cited by 274
In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells
Liebmann, J., Cook, J. A., Fisher, J., Teague, D., & Mitchell, J. B. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.441 · Cited by 267 · cited 1×
“Agents having shown potential synergy with radiation include platinum analogs [64], antimetabolites [65e67], and taxanes [68].”
BackgroundPatient Navigation in Breast Cancer: A Systematic Review
Robinson-White, S., Conroy, B., Slavish, K. H., & Rosenzweig, M. (2010) · Cancer Nursing · doi:10.1097/ncc.0b013e3181c40401 · Cited by 261 · cited 1×
“A ‘patient navigator’ can help the patient going through all phases of the cancer journey [16–20].”
BackgroundThompson, A. M., Jordan, L. B., Quinlan, P., Anderson, E., Skene, A., Dewar, J. A., Purdie, C. A., & the Breast Recurrence in Tissues Study Group (2010) · Breast Cancer Research · doi:10.1186/bcr2771 · Cited by 253 · cited 1×
“LoE changed since ABC1 from 2C to 1C based on new published data [128–130].”
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub3 · Cited by 252
Cortés, J., Fumoleau, P., Bianchi, G. V., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 249 · cited 1×
“The only available data regarding this issue come from a phase II single arm study [98].”
BackgroundSelf-citationCardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L. J., Kyriakides, S., Costa, A., Cufer, T., Albain, K. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp235 · Cited by 241 · cited 1×
“Available literature has been previously reviewed [12] and a recent Cochrane meta-analysis [102] confirms and provides level 1 evidence for this recommendation.”
BackgroundSelf-citationEl Saghir, N. S., Adebamowo, C. A., Anderson, B. O., Carlson, R. W., Bird, P. A., Corbex, M., Badwe, R. A., Bushnaq, M. A., Eniu, A., Gralow, J. R., et al. (2011) · The Breast · doi:10.1016/j.breast.2011.02.006 · Cited by 237 · cited 1×
“LABC occurs at first presentation in about one-fifth of breast cancer patients worldwide, with lower incidence in countries with established screening programmes but as high as 60% in some other countries [29].”
BackgroundParidaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, L., Cufer, T., Duchateau, L., Hamilton, A., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg362 · Cited by 230 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Self-citationSecond international consensus guidelines for breast cancer in young women (BCY2)
Paluch-Shimon, S., Pagani, O., Partridge, A. H., Bar-Meir, E., Fallowfield, L., Fenlon, D., Friedman, E., Gelmon, K., Gentilini, O., Geraghty, J., et al. (2016) · The Breast · doi:10.1016/j.breast.2015.12.010 · Cited by 227 · cited 1×
“Age may influence breast cancer treatment, but it should not be the guiding force [10, 22–24].”
BackgroundSelf-citationUpdate on Locally Advanced Breast Cancer
Giordano, S. H. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-521 · Cited by 223 · cited 1×
“Inoperable LABC is a heterogeneous designation encompassing a range of clinical situations from neglected low-grade ERpositive breast cancers to rapidly progressing usually ER-negative disease [30–33].”
BackgroundSelf-citationPiccart-Gebhart, M. J., Burzykowski, T., Buyse, M., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8399 · Cited by 216 · cited 1×
“Although taxanes can be used as first line therapy, they have not shown superior benefit to anthracyclines in a meta-analysis performed in a mostly taxane-naive, anthracycline-pretreated patient population [103].”
BackgroundSelf-citationBurstein, H. J., Keshaviah, A., Baron, A. D., Hart, R. D., Lambert‐Falls, R., Marcom, P. K., Gelman, R., & Winer, E. P. (2007) · Cancer · doi:10.1002/cncr.22885 · Cited by 214 · cited 1×
“Vinorelbine yielded equal or superior results to both paclitaxel and docetaxel, when combined with trastuzumab in the HER-2-positive ABC in the HERNATA [113] and TRAVIOTA trials [114].”
ResultSelf-citationByrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., Cybulski, C., Marczyk, E., Chrzan, R., Eisen, A., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3231 · Cited by 210
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martín, M., Nortier, J. W. R., Paterson, A. H. G., Rimawi, M. F., Cañada, J. M. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70589-8 · Cited by 209 · cited 2×
“The CALOR study [76], a randomized Phase 3 study, allocated 162 patients to either physician's choice chemotherapy or no chemotherapy.”
BackgroundMethodPatient Navigation: A Community Centered Approach to Reducing Cancer Mortality
Freeman, H. P. (2006) · Journal of Cancer Education · doi:10.1207/s15430154jce2101s_4 · Cited by 199 · cited 1×
“A ‘patient navigator’ can help the patient going through all phases of the cancer journey [16–20].”
BackgroundBiologic Basis for Combining Drugs With Radiation
WILSON, G., BENTZEN, S., & HARARI, P. (2006) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.001 · Cited by 198 · cited 1×
“Agents having shown potential synergy with radiation include platinum analogs [64], antimetabolites [65e67], and taxanes [68].”
BackgroundCrane, C. H., Abbruzzese, J. L., Evans, D. B., Wolff, R. A., Ballo, M. T., Delclos, M., Milas, L., Mason, K., Charnsangavej, C., Pisters, P. W. T., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02740-7 · Cited by 198
Talbot, D. C., Moiseyenko, V, Van Belle, S., O'Reilly, S. M., Alba Conejo, E., Ackland, S., Eisenberg, P., Melnychuk, D., Pienkowski, T., Burger, H.-U., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600261 · Cited by 181 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultStage IV breast cancer in the era of targeted therapy: Does surgery of the primary tumor matter?
Neuman, H. B., Morrogh, M., Gonen, M., Van Zee, K. J., Morrow, M., & King, T. A. (2010) · Cancer · doi:10.1002/cncr.24873 · Cited by 181
Masuda, N., Sagara, Y., Kinoshita, T., Iwata, H., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70373-4 · Cited by 179 · cited 1×
“Very few data exist on primary endocrine therapy in premenopausal women [42] and, therefore, it cannot be recommended outside of clinical trials.”
BackgroundLocally Advanced and Inflammatory Breast Cancer
Chia, S., Swain, S. M., Byrd, D. R., & Mankoff, D. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.15.0243 · Cited by 179
Amir, E., Clemons, M., Purdie, C. A., Miller, N., Quinlan, P., Geddie, W., Coleman, R. E., Freedman, O. C., Jordan, L. B., & Thompson, A. M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.006 · Cited by 176 · cited 1×
“LoE changed since ABC1 from 2C to 1C based on new published data [128–130].”
The results of radiation therapy for isolated local regional recurrence after mastectomy
Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., & Goodman, R. L. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90775-y · Cited by 172 · cited 2×
“Complete resection followed by locoregional radiotherapy results in a 5-year local regional control ranging from 60 to 77% [59,60].”
BackgroundHébert-Croteau, N., Brisson, J., Latreille, J., Rivard, M., Abdelaziz, N., & Martin, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.018 · Cited by 171 · cited 1×
“The use of treatment guidelines has been associated with a significant improvement in survival [7–9].”
Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G., Royce, M., McCall, L. M., Ewer, M. S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70502-3 · Cited by 170
Howell, A., Pippen, J., Elledge, R. M., Mauriac, L., Vergote, I., Jones, S. E., Come, S. E., Osborne, C. K., & Robertson, J. F. R. (2005) · Cancer · doi:10.1002/cncr.21163 · Cited by 163 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Baselga, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0448 · Cited by 163
Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., Jungi, W. F., Thürlimann, B., Cavalli, F., & Obrecht, J. P. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2071 · Cited by 162 · cited 1×
“Finally, systemic therapy (both endocrine and chemotherapy) has been shown to benefit patients after complete resection of a first locoregional isolated recurrence [75,76].”
BackgroundSelf-citationFirst international consensus guidelines for breast cancer in young women (BCY1)
Partridge, A. H., Pagani, O., Abulkhair, O., Aebi, S., Amant, F., Azim, H. A., Costa, A., Delaloge, S., Freilich, G., Gentilini, O. D., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.03.011 · Cited by 159
Self-citationPiccart, M. J., Holmes, A., Baselga, J. M., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Santillana, S., Pritchard, K. I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba4 · Cited by 154
Self-citationInflammatory Breast Cancer: What We Know and What We Need to Learn
Yamauchi, H., Woodward, W. A., Valero, V., Álvarez, R. H., Lucci, A., Buchholz, T. A., Iwamoto, T., Krishnamurthy, S., Yang, W. T., Reuben, J. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0039 · Cited by 150 · cited 1×
“Inoperable LABC is a heterogeneous designation encompassing a range of clinical situations from neglected low-grade ERpositive breast cancers to rapidly progressing usually ER-negative disease [30–33].”
BackgroundStockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M., Ackland, S. P., Fitzharris, B. M., van Hazel, G., Wilcken, N. R. C., Grimison, P., Nowak, A. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9101 · Cited by 150 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationSocial and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens
Griggs, J. J., Culakova, E., Sorbero, M. E. S., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2749 · Cited by 149 · cited 1×
“The use of treatment guidelines has been associated with a significant improvement in survival [7–9].”
Alba, E., Chacón, J. I., Lluch, A. M., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Seguí, M. Á., Ribelles, N., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2100-y · Cited by 147 · cited 1×
“However, which patients definitely benefit is not yet clear since there is also one negative GEICAM study adding carboplatin to EC-Docetaxel in basal-like breast cancer [52].”
BackgroundCombination versus sequential single agent chemotherapy for metastatic breast cancer
Dear, R. F.-G., McGeechan, K., Jenkins, M. C., Barratt, A. L., Tattersall, M. H. N., & Wilcken, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008792.pub2 · Cited by 143 · cited 1×
“Available literature has been previously reviewed [12] and a recent Cochrane meta-analysis [102] confirms and provides level 1 evidence for this recommendation.”
BackgroundMilla-Santos, A., Milla, L., Portella, J., Rallo, L., Pons, M., Rodes, E., Casanovas, J., & Puig-Gali, M. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000047126.10522.f9 · Cited by 142 · cited 1×
“500 mg, every 4 weeks) [77–88].”
Löser, D. A., Shibata, A., Shibata, A., Woodbine, L. J., Jeggo, P. A., & Chalmers, A. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1027 · Cited by 140 · cited 1×
“Several novel therapeutics are also being studied in the trial setting in combination with radiation, including EGFR inhibitors [69], HER-2 inhibitors [70], and poly (ADP-ribose) polymerase inhibitors [71].”
BackgroundPetrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2876-z · Cited by 133 · cited 1×
“In triple-negative breast cancer (TNBC), another putatively BRCA-deficient population, a relatively large amount of data from prospective studies, recently summarized in a meta-analysis, demonstrated improved pCR rates in patients whose neoadjuvant treatment included a platinum compound [49–51].”
BackgroundLetrozole in the neoadjuvant setting: the P024 trial
Ellis, M. J., & Ma, C. X. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9701-x · Cited by 133
Petrelli, F., & Barni, S. (2012) · Medical Oncology · doi:10.1007/s12032-012-0310-0 · Cited by 126 · cited 1×
“00001) [123].”
Brennan, M. E., & Houssami, N. (2011) · The Breast · doi:10.1016/j.breast.2011.10.005 · Cited by 121 · cited 1×
“Due to a relatively high risk of distant metastases [34], thoracic and abdominal CT scans are preferred to thorax X-ray and liver ultrasound, and a PET-CT is also an acceptable option [34].”
BackgroundSelf-citationLoibl, S., Volz, C., Mau, C. Y., Blohmer, J., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Hanusch, C. A., Jackisch, C., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2861-6 · Cited by 119 · cited 1×
“Data presented after ABC2 strongly suggest that this subset of breast cancer, especially lobular histology, is less sensitive to chemotherapy (at least in terms of pCR rate) [41].”
BackgroundSelf-citationGanz, P. A., Yip, C. H., Gralow, J. R., Distelhorst, S. R., Albain, K. S., Andersen, B. L., Bevilacqua, J. L. B., de Azambuja, E., Saghir, N. S. E., Kaur, R., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.049 · Cited by 118
Self-citationSurgery of the primary tumor does not improve survival in stage IV breast cancer
Dominici, L. S., Najita, J., Hughes, M. E., Niland, J. C., Marcom, P. K., Wong, Y., Carter, B., Javid, S. H., Edge, S. B., Burstein, H. J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1648-2 · Cited by 114
Ko, N. Y., Darnell, J. S., Calhoun, E. A., Freund, K. M., Wells, K., Shapiro, C. L., Dudley, D. J., Patierno, S. R., Fiscella, K. A., Raich, P. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6037 · Cited by 99 · cited 1×
“A ‘patient navigator’ can help the patient going through all phases of the cancer journey [16–20].”
BackgroundThe role of surgery in metastatic breast cancer
Ruiterkamp, J., & Ernst, M. F. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70142-3 · Cited by 90 · cited 1×
“All but one study published after this 2010 paper support the surgical removal of the primary tumour in patients with stage IV disease, reinforcing the importance of the ongoing prospective trials evaluating this approach since existing data come almost exclusively from retrospective studies [117– 121].”
BackgroundCardoso, F., Beşe, N., Distelhorst, S. R., Bevilacqua, J. L. B., Ginsburg, O., Grunberg, S. M., Gralla, R. J., Steyn, A., Pagani, O., Partridge, A. H., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.07.050 · Cited by 90 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundSelf-citationShien, T., Nakamura, K., Shibata, T., Kinoshitá, T., Aogi, K., Fujisawa, T., Masuda, N., Inoue, K., Fukuda, H., & Iwata, H. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys120 · Cited by 88 · cited 1×
“no treatment in stage IV patients at presentation [124,125].”
BackgroundKilburn, J. M., Kuremsky, J. G., Blackstock, A. W., Munley, M. T., Kearns, W. T., Hinson, W. H., Lovato, J. F., Miller, A. A., Petty, W. J., & Urbanic, J. J. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.11.017 · Cited by 87 · cited 1×
“The first results of retreatment with stereotactic body radiotherapy (SBRT) techniques have been published recently, describing promising local control rates [62].”
BackgroundBlackwell, K., Miles, D. W., Gianni, L., Krop, I. E., Welslau, M., Baselga, J. M., Pegram, M. D., Oh, D., Dieras, V. C., Olsen, S. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba1 · Cited by 84
Self-citationLin, N., Thomssen, C., Cardoso, F., Cameron, D., Čufer, T., Fallowfield, L. J., Francis, P. A., Kyriakides, S., Pagani, O., Senkus, E., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.03.006 · Cited by 84
Self-citationKoshy, N. V., Quispe, D., Shi, R., Mansour, R. P., & Burton, G. V. (2010) · The Breast · doi:10.1016/j.breast.2010.02.003 · Cited by 79 · cited 1×
“Fewer data exist for inclusion of platinum in the treatment of metastatic disease, although the benefit in the TNBC population seems to be larger than in other breast cancer patients [53].”
BackgroundRashaan, Z. M., Bastiaannet, E., Portielje, J. E. A., van de Water, W., van der Velde, S., Ernst, M. F., van de Velde, C. J. �., & Liefers, G. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.10.004 · Cited by 79
An update on male breast cancer and future directions for research and treatment
Sousa, B., Moser, E. C., & Cardoso, F. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.037 · Cited by 78 · cited 1×
“So peripheral conversion results in less than 5% of all testosterone, 80% of all dihydrotestosterone and oestradiol, and nearly all of estrone (98%) [56,57].”
BackgroundSelf-citationFoukakis, T., Fornander, T., Lekberg, T., Hellborg, H., Adolfsson, J., & Bergh, J. C. S. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1594-z · Cited by 73 · cited 2×
“Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6].”
BackgroundSelf-citationNguyen, D. H. A., Truong, P. T., Alexander, C., Walter, C. V., Hayashi, E., Christie, J. L., & Lesperance, M. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.11.046 · Cited by 73
Patient Navigation Through the Cancer Care Continuum: An Overview
Hopkins, J., & Mumber, M. P. (2009) · Journal of Oncology Practice · doi:10.1200/jop.0943501 · Cited by 71 · cited 1×
“A ‘patient navigator’ can help the patient going through all phases of the cancer journey [16–20].”
BackgroundChest wall resection in the treatment of locally recurrent breast carcinoma
Faneyte, I. F., Rutgers, E. J. T., & Zoetmulder, F. A. �. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970901)80:5<865::aid-cncr6>3.0.co;2-k · Cited by 70
Gelmon, K. A., Boyle, F. M., Kaufman, B., Huntsman, D. D., Manikhas, A., Leo, A. D., Martín, M., Schwartzberg, L. S., Dent, S. F., Ellard, S. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba671 · Cited by 68
Self-citationHorton, J. K., Halle, J. S., Ferraro, M., Carey, L., Moore, D. T., Ollila, D. W., & Sartor, C. I. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.027 · Cited by 66 · cited 1×
“Several novel therapeutics are also being studied in the trial setting in combination with radiation, including EGFR inhibitors [69], HER-2 inhibitors [70], and PARP inhibitors [71].”
BackgroundNeoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Fluoropyrimidine-radiation interactions in cells and tumors
Lawrence, T. S., Tepper, J. E., & Blackstock, A. W. (1997) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(97)80024-0 · Cited by 61 · cited 1×
“Agents having shown potential synergy with radiation include platinum analogues [64], antimetabolites, [65–67], and taxanes [68].”
BackgroundRuiterkamp, J., Voogd, A. C., Tjan‐Heijnen, V. C. G., Bosscha, K. P., van der Linden, Y. M., Rutgers, E. J. T., Boven, E., van der Sangen, M. J. C., & Ernst, M. F. (2012) · BMC Surgery · doi:10.1186/1471-2482-12-5 · Cited by 58 · cited 1×
“no treatment in stage IV patients at presentation [124,125].”
BackgroundRe-surgery and chest wall re-irradiation for recurrent breast cancer - a second curative approach
Müller, A., Eckert, F., Heinrich, V., Bamberg, M., Brucker, S. Y., & Hehr, T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-197 · Cited by 56 · cited 1×
“With modern radiotherapy techniques it is often possible to reirradiate with full dose without too many side effects [61].”
BackgroundWhen to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis, T., Åström, G., Lindström, L. S., Hatschek, T., & Bergh, J. C. S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds297 · Cited by 55 · cited 1×
“LoE changed since ABC1 from 2C to 1C based on new published data [128–130].”
Self-citationSikov, W. M., Berry, D., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Kuzma, C., Pluard, T., Somlo, G., Port, E. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s5-01 · Cited by 55
Self-citationvon Minckwitz, G., Schneeweiß, A., Salat, C., Rezai, M., Zahm, D. M., Klare, P., Blohmer, J., Tesch, H., Khandan, F., Jud, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.1004 · Cited by 55 · cited 1×
“In triple-negative breast cancer (TNBC), another putatively BRCA-deficient population, a relatively large amount of data from prospective studies, recently summarized in a meta-analysis, demonstrated improved pCR rates in patients whose neoadjuvant treatment included a platinum compound [49–51].”
BackgroundSelecting High Priority Quality Measures For Breast Cancer Quality Improvement
Hassett, M. J., Hughes, M. E., Niland, J. C., Ottesen, R. A., Edge, S. B., Bookman, M. A., Carlson, R. W., Theriault, R. L., & Weeks, J. C. (2008) · Medical Care · doi:10.1097/mlr.0b013e318178ead3 · Cited by 54 · cited 1×
“The use of treatment guidelines has been associated with a significant improvement in survival [7–9].”
Fluoropyrimidine-Radiation Interactions in Cells and Tumors.
Lawrence, T. S., Tepper, J. E., & Blackstock, A. W. (1997) · PubMed · doi:10.1053/srao00700260 · Cited by 54
Blum, J. L., Barrios, C. H., Feldman, N. R., Verma, S., Mckenna, E. F., Lee, L. F., Scotto, N., & Gralow, J. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2288-x · Cited by 50 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationKaufman, P. A., Awada, A. H., Twelves, C. J., Yelle, L., Perez, E. A., Wanders, J., Olivo, M., He, Y., & Dutcus, C. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s6-6 · Cited by 48
Badwe, R. A., Parmar, V. V., Hawaldar, R. W., Nair, N. S., Kaushik, R. V., Siddique, S., Navale, A., Budrukkar, A. N., Mittra, I., & Gupta, S. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s2-02 · Cited by 47
Loco-regional treatment in metastatic breast cancer patients: Is there a survival benefit?
Ly, B. H., Nguyen, N. P., Vinh‐Hung, V., Rapiti, E., & Vlastos, G. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0610-z · Cited by 47
Soran, A., Özmen, V., Ozbas, S., Karanlık, H., Müslümanoğlu, M., İğci, A., Cantürk, Z., Utkan, Z., Özaslan, C., Evrensel, T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-s2-03 · Cited by 45
Zagar, T. M., Higgins, K. A., Miles, E. F., Vujašković, Ž., Dewhirst, M. W., Clough, R. W., Prosnitz, L. R., & Jones, E. L. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.10.020 · Cited by 43 · cited 1×
“Recent studies have analysed the combination of radiotherapy, hyperthermia and concurrent chemotherapy in this patient population [74].”
Background(2007) · The Breast · doi:10.1016/j.breast.2006.11.002 · Cited by 39
Pivot, X. B., Семиглазов, В. Ф., Żurawski, B. A., Allerton, R., Fabi, A., Ciruelos, E. M., Parikh, R., DeSilvio, M., Santillana, S., & Swaby, R. F. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)34361-1 · Cited by 36
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
Skinner, H. D., Strom, E. A., Motwani, S. B., Woodward, W. A., Green, M. C., Babiera, G. V., Booser, D. J., Meric‐Bernstam, F., & Buchholz, T. A. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-13 · Cited by 34 · cited 1×
“Complete resection followed by locoregional radiotherapy results in a 5-year local regional control ranging from 60 to 77% [59,60].”
BackgroundBreast Cancer in Men-Should Aromatase Inhibitors Become First-Line Hormonal Treatment?
Nordman, I. C., & Dalley, D. N. (2008) · The Breast Journal · doi:10.1111/j.1524-4741.2008.00648.x · Cited by 29 · cited 1×
“So, peripheral conversion results in <5% of all testosterone, 80% of all dihydrotestosterone and estradiol, and nearly all of estrone (98%) [56, 57].”
BackgroundMesa, J. E. G., Barquinero, J. F., Lee‐Estévez, M., García, O., & Casacó, A. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.2.18439 · Cited by 28
Metastatic breast cancer patients: The forgotten heroes!
Cardoso, F. (2009) · The Breast · doi:10.1016/j.breast.2009.09.001 · Cited by 25
Self-citationPattern of care in locally advanced breast cancer: Focus on local therapy
Sinacki, M., Badzio, A., Wełnicka-Jaśkiewicz, M., Bogaerts, J., Piccart, M. J., Therasse, P., Smith, I. E., Hatschek, T., & Jassem, J. (2010) · The Breast · doi:10.1016/j.breast.2010.08.008 · Cited by 22 · cited 1×
“Primary systemic therapy in inoperable LABC allows breast conserving surgery in variable percentages depending on tumour/ patient characteristics [43].”
BackgroundSelf-citationACR Appropriateness Criteria® Locally Advanced Breast Cancer
MacDonald, S. M., Harris, E. E. R., Arthur, D. W., Bailey, L., Bellon, J. R., Carey, L., Goyal, S., Halyard, M. Y., Moran, M. S., Horst, K. C., et al. (2011) · The Breast Journal · doi:10.1111/j.1524-4741.2011.01150.x · Cited by 22
Swain, S., Kim, S.-B., Cortés, J., Ro, J., Семиглазов, В. Ф., Campone, M., Ciruelos, E. M., Ferrero, J.-M., Schneeweiß, A., Knott, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p5-18-26 · Cited by 18
Fiteni, F., Villanueva, C., Bazán, F., Perrin, S., Chaigneau, L., Dobi, E., Montcuquet, P., Cals, L., Méneveau, N., Nerich, V., et al. (2013) · The Breast · doi:10.1016/j.breast.2013.12.003 · Cited by 16 · cited 1×
“Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6].”
BackgroundPiccart, M. J., Hortobágyi, G. N., Campone, M., Pritchard, K. I., Noguchi, S., Rugo, H. S., Gnant, M., Feng, W., Taran, T., & Baselga, J. M. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)00221-4 · Cited by 16
Self-citation柏葉, 匡. (2007) · Mebio oncology · Cited by 14
Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC)
Byrski, T., Foszczynska-Kloda, M., Huzarski, T., Dent, R. A., Gronwald, J., Cybulski, C., Dębniak, T., Górski, B., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.1099 · Cited by 14 · cited 1×
“However, available data suggest their promising activity mostly in the neoadjuvant setting [46,47], and to a lesser degree in advanced disease [48].”
BackgroundBuzdar, A. U., Suman, V. J., Meric‐Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G. W., Royce, M., & Hunt, K. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.502 · Cited by 14
453 Trends in survival in metastatic breast cancer
Sundquist, M., Eriksson, Z., Brudin, L. H., & Tejler, G. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70474-2 · Cited by 12
Cox, C. L., Holloway, C. M., Shaheta, A., Nofech‐Mozes, S., & Wright, F. C. (2013) · Current Oncology · doi:10.3747/co.20.1214 · Cited by 7 · cited 24×
“I B 97.2% (36) Yes 2.7% (1) Abstain (37 voters) Since LABC patients have a significant risk of metastatic disease, a full staging workup, including a complete history, physical examination, lab tests and imaging of chest and abdomen (preferably CT scans) and bone, prior to initiation of systemic therapy is highly reco…”
BackgroundInfluentialWahl, A. O., & Small, W. C. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.037 · Cited by 6
Silverman, R., Smith, L., & Sundar, S. (2014) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2014-000654.159 · Cited by 3 · cited 1×
“It is important to clearly define the disease context with patients and families, addressing the concept of uncertainty and tailoring the treatment strategy according to individual priorities and disease status [28].”
BackgroundThe EUSOMA recommendations for the management of young women with breast cancer
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F. A., Delaloge, S., Marotti, L., et al. (2012) · Cited by 3
Self-citation
Research works printed but not linked: 2
- Piccart-Gebhart, 2014, J Clin Oncol, 32
- Wildiers, 2013, T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice, Presented at the European Cancer Congress
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
“Visceral crisis and endocrine resistance have been defined during ABC 2 and published [1].”
InfluentialSelf-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“MONARCH 2 evaluated patients whose disease progressed while they were receiving neoadjuvant or adjuvant ET, # 12 months after adjuvant ET, or while receiving ET for ABC.”
BackgroundInfluentialSelf-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
“MBC after therapy for EBC tends to have a more aggressive tumour biology and a worse outcome compared with de novo MBC. 14,15 In a retrospective cohort study covering the period 1990-2010, 14 de novo MBC incidence rates remained constant whereas subsequent MBC decreased.”
BackgroundInfluentialSelf-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“For the purpose of advanced breast cancer (ABC) guidelines, ABC comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).(1,2) Advanced/metastatic breast cancer remains a virtually”
Self-citation
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.